BCTX NASDAQ
BriaCell Therapeutics Corp.
1W: -6.5%
1M: +13.2%
3M: +15.4%
YTD: -43.6%
1Y: -67.9%
3Y: -99.6%
5Y: -99.1%
$4.04
-0.07 (-1.70%)
Weekly Expected Move ±10.9%
$3
$4
$4
$4
$5
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$148K
-29.0% ▼
Operating Income
-$38M
+17.2% ▲
Net Income
-$36M
-457.4% ▼
EPS (Diluted)
$-86.25
-44.5% ▼
EBITDA
-$37M
-453.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $19K | $19K | $21K | $115K | $148K |
| Gross Profit | -$19K | -$19K | -$21K | -$115K | -$148K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $3M | $10M | $21M | $37M | $30M |
| SG&A Expenses | $6M | $9M | $11M | $8M | $6M |
| Operating Expenses | $9M | $19M | $31M | $45M | $38M |
| Operating Income | -$9M | -$19M | -$31M | -$46M | -$38M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $100K | $1K | $0 | $0 | $51K |
| Income Before Tax | -$18M | -$34M | -$27M | -$7M | -$37M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$18M | -$34M | -$27M | -$7M | -$36M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-585.01 | $-330.38 | $-261.86 | $-59.69 | $-86.25 |
| EBITDA | -$18M | -$34M | -$27M | -$7M | -$37M |
| Shares Outstanding | 301305 | 1M | 1M | 1M | 2M |